Rovi
Rovi is a Madrid pharmaceutical group known for low-molecular-weight heparins and long-acting injectables; its bemiparin trials in cancer-associated thrombosis are why it appears among phase 3 cancer sponsors.
Overview
Laboratorios Farmacéuticos Rovi, founded in 1946 in Madrid and listed on the Spanish stock exchange, makes the low-molecular-weight heparin bemiparin, contract-manufactures injectables and develops long-acting formulations. Its phase 3 trials of bemiparin for preventing and treating venous thromboembolism in cancer patients are registered on ClinicalTrials.gov under Rovi as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyKissei Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.